Global Companion Animal Internal Dewormer Market Size By Type (Tablet, Powder), By Application (Dogs, Cats), By Region, And Segment Forecasts, 2023 to 2032

The Global Companion Animal Internal Dewormer Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.8 billion by 2031, growing at a CAGR of 7.4% during the forecast period (2023–2031). The market is driven by increasing pet ownership, rising awareness about pet health, and the growing prevalence of parasitic infections among companion animals. Internal dewormers are essential veterinary medicines used to treat and prevent infections caused by various endoparasites like roundworms, hookworms, and tapeworms in dogs, cats, and other companion animals. With growing expenditures on pet healthcare and increasing adoption of preventive veterinary care, the demand for internal deworming solutions is witnessing consistent growth worldwide.

Drivers:

1. Rise in Pet Ownership and Humanization of Pets:

The increasing number of households adopting pets and treating them as family members has led to higher spending on their health and wellness. This trend is especially prominent in developed regions, boosting the demand for premium veterinary pharmaceuticals, including internal dewormers.

2. Growing Awareness About Zoonotic Diseases:

Concerns over zoonotic disease transmission have encouraged pet owners to prioritize regular deworming as a preventive health measure. Educational campaigns by veterinary associations and pet health brands further reinforce this behavior.

3. Availability of Broad-Spectrum and Palatable Formulations:

Advancements in formulation technology have led to the development of broad-spectrum dewormers in chewable and flavored tablet forms, increasing ease of administration and compliance among pet owners.

Restraints:

1. Limited Access to Veterinary Services in Rural Areas:

Despite rising demand, limited veterinary infrastructure and awareness in some developing or rural regions restrict market penetration, especially for newer or branded dewormers.

2. Adverse Reactions and Drug Resistance:

Concerns about adverse effects and the emergence of anthelmintic resistance among parasites can reduce the effectiveness of certain drugs, leading to hesitancy among pet owners and veterinarians.

Opportunity:

1. Growth of E-commerce Veterinary Pharmacies:

The rising trend of online veterinary pharmacies is simplifying access to prescription dewormers, expanding market reach, especially in remote locations, and offering opportunities for personalized subscription-based deworming services.

2. Expansion in Emerging Economies:

Pet care spending is growing rapidly in countries such as India, Brazil, and Southeast Asia, where awareness and access to veterinary services are improving, offering fertile ground for market expansion.

Market by System Type Insights:

By system type, the Tablets & Chewables segment held the largest market share in 2023. These products are favored for their ease of administration, palatability, and effectiveness. This segment is expected to continue its dominance owing to innovations in flavoring and targeted deworming capabilities. The Spot-On Treatments segment is anticipated to register the fastest growth, driven by increasing consumer preference for topical solutions that combine deworming with flea and tick control.

Market by End-use Insights:

Based on end-use, Veterinary Clinics accounted for the largest share in 2023, driven by growing pet visits for routine check-ups and preventive care. Home-based Pet Care is an emerging segment, propelled by the increasing trend of self-administered pet healthcare and availability of OTC deworming products under veterinary guidance.

Market by Regional Insights:

North America led the global market in 2023, driven by high pet adoption rates, advanced veterinary care infrastructure, and proactive deworming programs. However, Asia-Pacific is projected to register the highest CAGR during the forecast period, supported by rising pet ownership, expanding middle class, and increasing availability of companion animal healthcare solutions in countries like China and India.

Competitive Scenario:

Key players in the Global Companion Animal Internal Dewormer Market include Boehringer Ingelheim, Zoetis Inc., Elanco Animal Health, Merck Animal Health, Virbac, Bayer AG, Ceva Santé Animale, Vetoquinol, Dechra Pharmaceuticals, and KRKA d.d. These companies are investing in product innovation, regional expansion, and strategic acquisitions to strengthen their competitive position.

Scope of Work – Global Companion Animal Internal Dewormer Market

Key Market Developments:

2023: Zoetis launched a next-generation broad-spectrum chewable dewormer combining efficacy against multiple parasites with improved taste for higher compliance.

2024: Elanco Animal Health introduced a home-delivery subscription model for internal dewormers, targeting busy urban pet owners.

2025: Boehringer Ingelheim expanded its production facility in Southeast Asia to meet the rising demand for veterinary pharmaceuticals in emerging markets.

FAQs:

1. What is the current market size of the Global Companion Animal Internal Dewormer Market?

The market was valued at USD 2.1 billion in 2023.

2. What is the major growth driver of the Global Companion Animal Internal Dewormer Market?

Increasing pet ownership and heightened awareness of zoonotic disease prevention are key drivers.

3. Which is the largest region during the forecast period in the Global Companion Animal Internal Dewormer Market?

North America held the largest share in 2023, while Asia-Pacific is projected to grow fastest through 2031.

4. Which segment accounted for the largest market share in the Global Companion Animal Internal Dewormer Market?

The Tablets & Chewables segment led the market in 2023.

5. Who are the key market players in the Global Companion Animal Internal Dewormer Market?

Key players include Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim, Merck Animal Health, and Virbac.